Wellington Management Group
TCRR

Wellington Management Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Wellington Management Group’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-835,327
Closed -$3.89M – 2290
2021
Q4 		$3.89M Sell
835,327
-1,909,849
-70% -$11.9M ﹤0.01% 1523
2021
Q3 		$23.4M Sell
2,745,176
-2,589,162
-49% -$36.6M ﹤0.01% 1050
2021
Q2 		$87.5M Buy
5,334,338
+398,244
+8% +$8.04M 0.01% 669
2021
Q1 		$109M Buy
4,936,094
+1,182,730
+32% +$32.2M 0.02% 595
2020
Q4 		$116M Buy
3,753,364
+1,762,274
+89% +$44.6M 0.02% 552
2020
Q3 		$40.5M Buy
+1,991,090
New +$35M 0.01% 753

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Wellington Management Group's TCRR Position: Q1 2022 in Review

Wellington Management Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 835,327 shares — an estimated $3.89M sold.

Wellington Management Group first reported a position in TCRR in Q3 2020 and held it in 6 quarters. The position peaked at $116M in Q4 2020. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Wellington Management Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Wellington Management Group sold 835,327 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $3.89M.
  • Wellington Management Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 6 quarters.
  • Wellington Management Group's TCR2 Therapeutics Inc. Common Stock position peaked at $116M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Wellington Management Group's 13F filing for Q1 2022, filed 16 May 2022.